NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases

A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial ...

NovelMed Advances NM5072 for Multiple Ocular Disorders

Biogen’s acquisition of Apellis highlights interest in complement-based ophthalmology and multi-indication platforms. NM5072 represents a broad multi-indication opportunity, supported by preclinical ...

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically ...
The New England Journal of Medicine

Iptacopan in IgA Nephropathy — Final 24-Month Data

Overactivation of the alternative complement pathway contributes to IgA nephropathy and glomerular inflammation. In the 9-month interim analysis of this phase 3 trial, iptacopan, a complement factor B ...

Novartis Pharma AG: Novartis Fabhalta (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...